Novo Nordisk expects the deal to close by the end of the year, the company said in an Aug. 10 news release. Earlier that day, the drugmaker also said it would extend supply limits for its popular weight loss drug Wegovy.
Inversago is a Canada-based drugmaker with 22 employees focused on developing treatments for diabetes, obesity and other metabolic conditions that target a protein called cannabinoid receptor one, which plays a role in metabolism and appetite regulation. Its lead drug candidate is an oral therapy that, according to results from a phase 1 trial, helped participants lose an average of nearly 8 pounds over the 28-day treatment period.
Novo Nordisk’s blockbuster drugs Wegovy and Ozempic are injectables that work by mimicking GLP-1 to suppress appetite and delay the passage of food in the stomach.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
